https://www.selleckchem.com/pr....oducts/inaxaplin.htm
The chemotherapy exposure during chemoradiotherapy for rectal cancer is adequate for radiosensitization but suboptimal for treatment of distant micrometastasis. This study aimed to determine tolerability, dose intensity, response, and toxicity of a novel intensified neoadjuvant treatment approach. Eligible patients were MRI-staged T3-4NxM0 rectal adenocarcinoma. Treatment consisted of FOLFOX chemotherapy given in weeks 1, 6, and 11 with pelvic radiotherapy (25.2Gy in 3weeks in 1.8Gy/fraction with oxaliplatin and 5-FU continuous infusi
Like
Comment
Share
